Here we demonstrated elevated levels of C5a and sC5b-9 in COVID-19 patients compared to a broad control population in an inpatient and outpatient setting, consisting mostly of patients with viral respiratory infection other than COVID-19, bacterial pneumonia but also with systemic inflammatory response syndromes secondary to non-infectious etiologies. This evidence concerns the gene C5 and COVID-19.